



## Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences

February 6, 2017

### *Presentations to be Webcast on Feb. 15 and February 22*

WATERTOWN, Mass.--(BUSINESS WIRE)--Feb. 6, 2017-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at each of the following investor conferences:

- February 15, 2:30 p.m. ET – LEERINK Partners 6<sup>th</sup> Annual Global Healthcare Conference, New York
- February 22, 2:35 p.m. ET – RBC Capital Markets 2017 Global Healthcare Conference, New York

A live webcast and replay of each presentation will be accessible by visiting the "Calendar of Events" section on the "Investors" page of Enanta's website at [www.enanta.com](http://www.enanta.com). The webcast replay will be available following each presentation and will be archived for approximately 30 days.

### **About Enanta**

Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. Enanta's research and development efforts are currently focused on the following disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Enanta has discovered novel protease inhibitors for use against the hepatitis C virus (HCV). These protease inhibitors, developed through Enanta's collaboration with AbbVie, include paritaprevir, currently marketed in AbbVie's HCV regimens, and glecaprevir (ABT-493), Enanta's second protease inhibitor product, which AbbVie is developing as part of its investigational HCV regimen of glecaprevir/pibrentasvir (G/P) currently under regulatory review in the U.S. and the E.U. Royalties and any further milestone payments from this collaboration will provide funding for Enanta's earlier development programs, including its Phase 1 FXR agonist program for NASH/PBC, and its preclinical programs for HBV and RSV. Please visit [www.enanta.com](http://www.enanta.com) for more information on Enanta's programs and pipeline.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20170206005725/en/>

Source: Enanta Pharmaceuticals, Inc.

### **Investor Contact**

Enanta Pharmaceuticals, Inc.  
Carol Miceli, 617-607-0710  
[cmiceli@enanta.com](mailto:cmiceli@enanta.com)

or

### **Media Contact**

MacDougall Biomedical Communications  
Kari Watson, 781-235-3060  
[kwatson@macbiocom.com](mailto:kwatson@macbiocom.com)